Repligen (NASDAQ:RGEN) Director Anthony Hunt Sells 20,000 Shares of Stock

Repligen Corporation (NASDAQ:RGEN) Director Anthony Hunt sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $154.61, for a total value of $3,092,200.00. Following the completion of the sale, the director owned 80,743 shares of the company’s stock, valued at $12,483,675.23. This represents a 19.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Anthony Hunt also recently made the following trade(s):

• On Wednesday, November 12th, Anthony Hunt sold 25,000 shares of Repligen stock. The shares were sold at an average price of $156.88, for a total transaction of $3,922,000.00.

Repligen Price Performance

RGEN traded up $1.81 during trading on Friday, hitting $152.37. The company’s stock had a trading volume of 1,586,272 shares, compared to its average volume of 826,954. The firm’s 50 day moving average price is $141.04 and its two-hundred day moving average price is $129.77. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.58 billion, a price-to-earnings ratio of 7,622.31, a price-to-earnings-growth ratio of 3.32 and a beta of 1.15. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The business had revenue of $188.81 million during the quarter, compared to analysts’ expectations of $181.23 million. During the same period in the previous year, the business posted $0.43 earnings per share. The firm’s revenue for the quarter was up 21.9% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Sell-side analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RGEN. Evercore ISI upped their price objective on Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Wells Fargo & Company cut their target price on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 30th. Barclays boosted their price target on shares of Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group upped their target price on shares of Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a research report on Wednesday, October 29th. Finally, Jefferies Financial Group set a $160.00 price objective on Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $173.85.

Institutional Investors Weigh In On Repligen

Hedge funds and other institutional investors have recently bought and sold shares of the company. Twin Tree Management LP acquired a new stake in shares of Repligen in the first quarter valued at approximately $29,000. Hantz Financial Services Inc. boosted its position in Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 293 shares during the last quarter. Signaturefd LLC raised its stake in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 128 shares in the last quarter. CWM LLC grew its stake in shares of Repligen by 67.2% in the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 135 shares in the last quarter. Finally, Center for Financial Planning Inc. raised its position in Repligen by 34.2% during the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 126 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.